Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibiotics: where did we go wrong?

Karen M Overbye1, John F Barrett

  • 1Antibacterial Discovery, Department of Infectious Diseases, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, NJ 08876, USA.

Drug Discovery Today
|January 29, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibacterial and mechanism of action studies of boxazomycin A.

The Journal of antibiotics·2024
Same author

Overview of anti-infective drug development.

Current protocols in pharmacology·2011
Same author

Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa.

Journal of natural products·2009
Same author

Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa.

Bioorganic & medicinal chemistry·2008
Same author

Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347.

Journal of the American Chemical Society·2008
Same author

Control and prevention of MRSA infections.

Methods in molecular biology (Clifton, N.J.)·2007
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
See all related articles

The pharmaceutical industry has deprioritized antibacterial research despite ongoing infectious disease mortality. This decline in antibiotic discovery, alongside rising drug-resistant bacteria, poses a significant public health risk.

Area of Science:

  • Microbiology
  • Pharmacology
  • Public Health

Background:

  • Antibacterial research funding declined significantly in the late 1960s.
  • This shift occurred despite infectious diseases remaining a leading global cause of mortality.
  • Declining industrial support for antimicrobial research is a multifaceted issue.

Purpose of the Study:

  • To analyze the reasons behind the decline in antibacterial drug discovery.
  • To highlight the public health threat posed by drug-resistant bacterial infections.
  • To underscore the waning industrial support for antimicrobial research.

Main Methods:

  • Literature review on historical trends in pharmaceutical research and development.
  • Analysis of factors influencing antibacterial research investment.

Related Experiment Videos

  • Assessment of the impact of antimicrobial resistance on public health.

    • Main Results:

    • The pharmaceutical industry has shifted focus away from antibacterials.
    • Bacterial infections remain a major cause of death worldwide.
    • Decreased investment in antibiotic discovery exacerbates the threat of drug-resistant pathogens.

    Conclusions:

    • The reduction in antibacterial research is driven by scientific, medical, marketing, and business factors.
    • The rise of drug-resistant bacteria presents a clear and present danger to public health.
    • Urgent attention and renewed investment are needed to address the crisis in antibiotic discovery.